![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
CMED HIFU Development Corporation |
---|---|
Information provided by: | CMED HIFU Development Corporation |
ClinicalTrials.gov Identifier: | NCT00637364 |
This is an open-label, non-randomized, single-center, therapeutic trial in patients with AJCC Stage III or IV pancreatic cancer with tumor related abdominal and/or back pain to evaluate the safety of high intensity focused ultrasound therapy using the FEP-BY02 HIFU system for palliation of pancreatic cancer-related pain. Patients meeting all eligibility criteria without any exclusion criteria will be offered an opportunity to participate in the study. After obtaining informed consent a baseline history, physical examination, laboratory studies, and any additional imaging studies needed will be performed.
The major theoretic risk to the patient with this procedure is the development of acute pancreatitis. If acute pancreatitis were to develop, it should become clinically evident by day 3 following HIFU ablation. Therefore, the initial phase of this pilot study is designed to allow a sufficient interval between HIFU treatments to identify whether this theoretic risk will manifest clinically. Previous clinical experience in China suggests that HIFU of pancreatic tumors is safe without risk of developing severe acute pancreatitis.
Patients treated with HIFU will have approximately 15-20% of the tumor volume treated per session. The first 5 patients (feasibility study) will receive their first HIFU treatment followed by a 3-5 day interval for observation. Following the feasibility study the results will be reviewed with the FDA. If no serious adverse events are encountered, and the FDA agrees with continuing the study, then the next 5 patients will be treated with an interval of 2-3 days between each treatment. If no serious adverse events are encountered in this group, then the next group of 5 patients will be treated at intervals of 1-2 days between each treatment.
Condition | Intervention | Phase |
---|---|---|
Pain Pancreatic Adenocarcinoma Ductal Adenocarcinoma |
Procedure: High intensity focused ultrasound, HIFU |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | An Open Label, Non-Randomized, Single-Center, Therapeutic Trial Examining the Feasibility, Safety, and Efficacy of FEP-BY02, a High Intensity Focused Ultrasound Tumor Treatment Device, in Patients With Pancreatic Cancer Pain |
Estimated Enrollment: | 5 |
Study Start Date: | March 2008 |
Estimated Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
The FEP-BY02 HIFU system uses extracorporeal generated high intensity ultrasound, focused on a tumor region of interest, to ablate tissue. A stand-alone B-mode ultrasound is used to locate and define the tumor region of interest. Once defined, the acoustic energy is delivered using a large aperture; fixed focus; sparse transducer array. The concentration of acoustic energy may result in thermal and/or mechanical bioeffects including tissue necrosis, apoptosis, and/or disruption (temporary or permanent) of normal cellular function within the targeted volume (such as nerve conduction).
The FEP-BY02 High Intensity Focused Ultrasound (HIFU) system is intended to ablate ductal adenocarcinoma of the pancreas with ultrasound-guided targeted delivery of focused ultrasound energy to effect thermal and/or mechanical bioeffects leading to ablation (destruction) of the targeted tumor tissue.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Washington | |
University of Washington | |
Seattle, Washington, United States, 98195 |
Principal Investigator: | Joo Ha Hwang, MD, PhD | University of Washington |
Responsible Party: | University of Washington ( Joo Ha Hwang, MD, PhD ) |
Study ID Numbers: | FEP-BY02-01, WIRB 20071832 |
Study First Received: | March 12, 2008 |
Last Updated: | January 12, 2009 |
ClinicalTrials.gov Identifier: | NCT00637364 History of Changes |
Health Authority: | United States: Food and Drug Administration |
pain pancreas pancreatic cancer pancreatic adenocarcinoma ductal adenocarcinoma |
Digestive System Neoplasms Skin Diseases Pancreatic Neoplasms Breast Neoplasms Endocrine System Diseases Pain Pancrelipase Carcinoma Carcinoma, Ductal |
Digestive System Diseases Gastrointestinal Neoplasms Pancreatic Diseases Carcinoma, Ductal, Breast Endocrinopathy Adenocarcinoma Breast Diseases Neoplasms, Glandular and Epithelial Endocrine Gland Neoplasms |
Neoplasms by Histologic Type Digestive System Neoplasms Skin Diseases Pancreatic Neoplasms Breast Neoplasms Endocrine System Diseases Carcinoma Carcinoma, Ductal Neoplasms |
Neoplasms by Site Digestive System Diseases Pancreatic Diseases Carcinoma, Ductal, Breast Neoplasms, Ductal, Lobular, and Medullary Adenocarcinoma Breast Diseases Neoplasms, Glandular and Epithelial Endocrine Gland Neoplasms |